OncoDxRx’s Breakthrough Technology Advances Gene-Drug Matching

Los Angeles, California — With its proprietary, one-of-a-kind and transformative technology, multiplied by exclusive knowhow and trade secret, OncoDxRx offers a menu of innovative blood-based tests that enable cancer patients to begin personalized treatment earlier than ever before. It's the ONLY company that can provide a portfolio of fit-for-purpose and competition-free assays using ONE simple tube of blood. Unlike other "Liquid Biopsy" diagnostics on the market, OncoDxRx's trade secrets will guarantee technological barriers that no one will cross, differentiating itself from competitors and securing a top-notch and unchallengeable position in this industry.

“OncoDxRx’s PGA (Patient-derived Gene expression-informed Anti-cancer drug efficacy) technology is a big step in the right direction to individualize ALL therapy to spare patient’s the side effects of drugs that will not work against their cancer, as well as to steer them to the right therapies against which their cancer will likely respond,” the company said. “It is functional precision medicine, it’s not just about the genetics and the targets but also about using the right drugs for the right patients.”

“PGA technology is mature, fully verified and validated and commercially ready in contrast to academic patent office’s early-stage projects and many other proof-of-concept pending inventions. We significantly mitigate potential risk through CLIA/CAP validation, patent protection, peer-reviewed publications and pilot clinical trials. Most importantly, the one-of-a-kind and market-driven PGA technology can be quickly implemented in a regular lab within weeks without large capital investment. This is how we win the market today and tomorrow.” The company noted.

OncoDxRx’s goal is to move quickly and complete three PGA validation (PGA lung, PGA pancreatic and PGA breast), and seeking for investors/partners and licensing/buyout opportunity in parallel, the company concluded.